Atossa Therapeutics, Inc. (ATOS) Q4 2023 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Atossa Therapeutics, Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.189 -- 00:00:03.930 Thank you for joining us this morning to discuss our full 00:00:03.930 -- 00:00:06.111 year 2023 results. 00:00:06.111 -- 00:00:11.432 On the call with me today is Carlo Desaro-Biondo, our group COO, 00:00:11.432 -- 00:00:15.553 and Jacques-Francois Deprest, our group CFO. 00:00:15.553 -- 00:00:19.555 And for the agenda today, I will share some key messages related to our accomplishments 00:00:19.555 -- 00:00:21.395 in 2023, 00:00:21.395 -- 00:00:25.646 as well as current strategic initiatives underway. 00:00:25.646 -- 00:00:30.910 Carla will cover in more details our performance bylines of business and regions. 00:00:30.910 -- 00:00:35.273 And then Jack Francois will go over our financial statement for the year. 00:00:35.273 -- 00:00:40.235 I'll come back with closing remarks, and then we'll take your Q&As. 00:00:40.297 -- 00:00:44.160 Before we get started, I want to draw your attention to the disclaimer that you'll find 00:00:44.160 -- 00:00:47.100 on slide three. And 00:00:48.823 -- 00:00:54.486 then you see the agenda. So let me move on to review the year. 00:00:54.793 -- 00:00:59.835 year end and you can see from the slide, we delivered group revenue and operating margin 00:00:59.835 -- 00:01:02.296 results that 00:01:02.296 -- 00:01:06.958 were in line with our full year guidance. This is my key messages. 00:01:06.958 -- 00:01:11.820 Our evident business reported continued growth and increased profitability in an environment 00:01:11.820 -- 00:01:16.402 where we saw a market softness in the Americas and in Northern Europe, particularly during 00:01:16.402 -- 00:01:19.423 the second half of the year. 00:01:19.423 -- 00:01:25.151 For the fiscal 23 tech foundations executed on this transformation plan, 00:01:25.151 -- 00:01:30....